

# Formulation and Evaluation of Mucoadhesive Film for the Treatment of Migraine

Aswathi Ak, Dr. Rama Bukka\*

Department of Pharmaceutics, Nargund college of pharmacy, Bangalore-85, Karnataka.

Submitted: 08-12-2022

Accepted: 17-12-2022

## ABSTRACT

Zolmitriptan is an antimigraine agent belonging to the group of triptans. Zolmitriptan relieves migraine headaches by inhibition of pro-inflammatory neuropeptide release. It is a BCS class II drug (low solubility and high permeability). Optimization of mucoadhesive film formulation was studied by using Carbopol 934 and HPMC K4M polymers and poly ethylene glycol used as plasticizer. The factors are studied at three levels which are responsible for the mucoadhesive strength, in-vitro residence time, swelling index and in-vitro drug release. Preformulation study was carried out includes drug estimation method, drug excipients compatibility study and melting point determination. The drug estimation was found to be linear between 3 to 24  $\mu\text{g/ml}$  and  $\lambda_{\text{max}}$  was found to be 219 nm. The FT-IR spectrum of drug-excipient was found to be satisfactory, which indicated that excipients were compatible with the drug. Zolmitriptan mucoadhesive films were prepared by solvent casting method with different concentration of excipients Carbopol 934 (0.5-1%) and HPMC K4M (3-5%). The mucoadhesive strength of the films was found in the range of 9.95-22.31%, In-vitro residence time 78-245 min, swelling index 12.79-29.7%, In-vitro drug release at 7<sup>th</sup>hr 52.606-92.088%. Among the nine formulations F3 was selected as optimized formulation

**Keywords:** Mucoadhesive formulations, Zolmitriptan, Carbopol 934, HPMC K<sub>4</sub>M, Solvent casting method, Design of experiment software.

## I. INTRODUCTION

Migraine is believed to be primary a neurological disorder that is characterized by recurrent headache that are moderate to severe. Typically, it affects one side of the head, are pulsating in nature, and lasts from a few hours to three days.

Associated symptoms may include nausea, vomiting and sensitivity to light, sound or smell. The pain is generally made worse by physical activity, although regular exercise may have

prophylactic effects. Up to one-third of people affected have aura; typically, a short period of visual disturbance that signals that the headache will soon occur. Migraine is believed to be due to a mixture of environmental and genetic factors. The risk of migraine usually decreases during pregnancy and after menopause. The underlying mechanisms are not fully known. They are, however, believed to involve the nerves and blood vessels of the brain. (1)

Mucoadhesive drug delivery systems prolong the residence time of the dosage form at the site of application or absorption. They facilitate an intimate contact of the dosage form with the underlying absorption surface and thus improve the therapeutic performance of the drug. In recent years, many such mucoadhesive drug delivery systems have been developed for oral, buccal, nasal, rectal and vaginal routes for both systemic and local effects.

Dosage forms designed for mucoadhesive drug delivery should be small and flexible enough to be acceptable for patients and should not cause irritation. Other desired characteristics of a mucoadhesive dosage form include high drug loading capacity, controlled drug release (preferably unidirectional release), good mucoadhesive properties, smooth surface, tastelessness, and convenient application. Erodible formulations can be beneficial because they do not require system retrieval at the end of desired dosing interval. A number of relevant mucoadhesive dosage forms have been developed for a variety of drugs.

Mucoadhesive films may be preferred over adhesive tablets in terms of flexibility and comfort. In addition, they can circumvent the relatively short residence time of oral gels on the mucosa, which are easily washed away and removed by saliva. Moreover, in the case of local delivery for oral diseases, the films also help protect the wound surface, thus helping to reduce pain, and treat the disease more effectively. An ideal film should be flexible, elastic, and soft, yet

adequately strong to withstand breakage due to stress from mouth movements. It must also possess good mucoadhesive strength in order to be retained in the mouth for the desired duration of action. Swelling of film, if it occurs, should not be too extensive in order to prevent discomfort.(2)

Triptans such as Zolmitriptan, Sumatriptan, Rizatriptan, etc are medications used to stop an active migraine headache (an abortive medication). Triptans are initially recommended treatments for those with moderate to severe pain from an acute migraine headache or those with milder symptoms who do not respond to simple analgesic. Triptans is effective for both pain and nausea in up to 75% of people. There are different method or routes of administration to take triptans drugs including oral (by mouth), injectable (subcutaneous), rectal, nasal spray, and oral dissolving tablets.

## II. MATERIALS AND METHOD

### Material

Zolmitriptan was obtained from Travancore chemical industry, Kerala. Carbopol 934 was obtained from Oryn Healthcare Ltd, Ahmedabad, Gujarat, Hydroxy Propyl Methyl Cellulose K4M from Otto chemei Pvt.Ltd. Mumbai, Maharashtra, Polyethylene Glycol-400 from Anamol Laboratories Pvt.Ltd, Palghar, Methanol was obtained from S.D. Fine Chem.Ltd. Mumbai.

### Methods

#### Preformulation studies

#### Identification of Drug by FT-IR

Weighed amount of drug was mixed with IR grade of Potassium Bromide (1:10) and compressed under 10-ton pressure in a hydraulic press to form a transparent pellet. The pellets were scanned by IR spectrophotometer over a range  $400\text{ cm}^{-1}$  to  $4000\text{ cm}^{-1}$ .

#### Melting point determination

Melting point of Zolmitriptan was determined by capillary tube method. Fine powder of the drug was filled into a glass capillary tube which was previously sealed at one end. The capillary tube tied to a thermometer was subjected to increasing temperatures and the temperature at which Zolmitriptan melts was recorded. This was repeated for three times and average reading recorded. (3)

### Preparation of Calibration curve of Zolmitriptan

**Stock-1 solution:** 100mg of Zolmitriptan was accurately weighed and dissolved in 30ml of methanol in a 100ml volumetric flask. Then the volume was made up to 100ml using pH 7.4 phosphate buffer and shaken well to get a  $1000\mu\text{g/ml}$  solution (primary stock solution).

**Stock-2 solution:** 2.5ml was pipetted out from primary stock solution into 25ml volumetric flask and the volume was made up to the mark with phosphate buffer (pH 7.4) to give a  $100\mu\text{g/ml}$  solution (secondary stock solution).

**Serial dilution:** From this solution ( $100\mu\text{g/ml}$ ) 0.3,0.6,0.9,1.2,1.5,1.8,2.1 and 2.4ml was pipetted out into and diluted to 10ml volumetric flask and using pH 7.4 to get aliquots of 3,6,9,12,15,18,21 and  $24\mu\text{g/ml}$  respectively.

The absorbance was measured at 219 nm using UV visible spectrophotometer. The standard graph was repeated three times ( $n=3$ ). The mean data was plotted by taking the concentration on X-axis and absorbance on Y-axis.

### Preparation of drug loaded mucoadhesive films

The drug Zolmitriptan loaded mucoadhesive films were prepared by solvent casting method. HPMC K4M and Carbopol 934 were used as film forming and mucoadhesive polymer respectively. Polyethylene glycol-400 used as plasticizer. Methanol used as solvent (drug solubility). It was designed to prepare a film  $1\times 1\text{ cm}^2$  to contain 2.5 mg of drug. The total area of casting is 49 square cm. According to this, calculated amount of drug equivalent to 0.1225 g of drug Zolmitriptan was weighed and transferred in to 100 ml beaker added with 5 ml methanol to that and mix it well. Required quantity of HPMC K4M and Carbopol 934 were weighed and dissolved in 20 ml of methanol and stirred with magnetic stirrer until it gets fully dissolved. The beaker was sealed using aluminium foil to avoid evaporation. After that the prepared drug solution was slowly added into the polymeric mixture and stirrer for 2 hrs and 0.15 ml of polyethylene glycol-400 (10% of polymer concentration) was added in to the drug polymer solution and mix it well. After completely dissolving, the mixture was poured square shaped plate made up of aluminium foil with side 7cm and the total area would be 49 square cm. This was placed on horizontal surface adjusted using spirit level. The polymer solution containing drug was carefully spread over 49 square cm area without any air bubble entrapment. The formulation kept in room temperature for drying till 14 hr. Each

mucoadhesive film are cut by the measurement of 1×1 cm<sup>2</sup> which contains dose equivalent to 2.5 mg. Total nine formulation of mucoadhesive films done by different concentration of polymers. The minimum concentration of HPMC K4M 3% and

Carbopol 934 0.5% and the maximum concentration of HPMC K4M 5% and Carbopol 934 1%. Formulations were prepared using Face Centered Central Composite Design using Design Expert Version 11.

**Table 1: Formulation chart of Zolmitriptan mucoadhesive films (F1-F9)**

Formulation code	Amount of drug (g)	HPMC K4M (g)	Carbopol 943 (g)	Polyethylene Glycol (ml)	Methanol (ml)
F1	0.122	1.25	0.125	0.137	25
F2	0.122	1.25	0.187	0.143	25
F3	0.122	1.25	0.25	0.15	25
F4	0.122	0.75	0.125	0.087	25
F5	0.122	0.75	0.187	0.097	25
F6	0.122	0.75	0.25	0.1	25
F7	0.122	1	0.125	0.112	25
F8	0.122	1	0.187	0.118	25
F9	0.122	1	0.25	0.125	25

**Evaluation of mucoadhesive films of Zolmitriptan**

**Weight Uniformity**

Ten films of each batch of formulation were weighed individually by using a digital weighing balance, and average weight of the films was calculated.(4)

**Folding endurance**

The folding endurance was measured manually. A small strip of film measuring 1×1cm<sup>2</sup> of each formulation was taken and folded at the same place till it broke or folded up to 300 times manually. The number of times a film could be folded at the same place gave the value of folding endurance. Average of three determinations was calculated.(4)

**Thickness of film**

Thickness of the mucoadhesive film was measured by Vernier callipers with the least count of 0.01mm at different spots of the film. The thickness was measured at ten different spots of the plane surface of films and the average film thickness and standard deviation was calculated.(4)

**Mucoadhesive strength**

In this study, Porcine buccal mucosa was employed as a biological membrane due to similarities with human buccal tissue. A modified physical balance method was used for determining the ex-vivo mucoadhesive strength. Fresh porcine buccal mucosa was obtained from a local slaughter house and used within 2 h of slaughter. The mucosal membrane was separated by removing the underlying fat and loose tissues using blunt forceps

and scissors intermittently dipping the tissue in hot water. The collected tissues were washed with distilled water, placed in normal saline solution at 4°C to maintain freshness and immediately used for experiment. Then the tissues were cut by scissors to approximate size of mucoadhesive film.

Modification of physical balance: left hand side pan was removed and replaced with glass block with flat surface below. Height of glass block was adjusted such that when balanced it would exactly touch the flat surface of the 500 ml beaker kept on inverted position placed exactly below the hanging glass block. Two sides of the balance were made equal before the study by keeping a 5g weight on the right side. Porcine Buccal mucosa was then stuck on to the bottom flat surface of the 500 ml beaker using cyanoacrylate adhesive such that mucosal surface faces upward. The beaker containing mucosal membrane was kept below the left hand set up of the balance. The buccal film was stuck to the lower flat side of hanging glass assembly with cyanoacrylate adhesive glue. The exposed film surface was moistened with distilled water and left for 30 s for initial hydration and swelling. Then the platform was slowly raised until the film surface came in contact with mucosa. A weight of 5 g was removed from the right hand pan, which lowered the pan along with the film over the mucosa. The balance was kept in this position for 3 minutes contact time. Then weights were slowly added to the right hand pan until the film detached from the mucosal surface. This detachment force gave the mucoadhesive strength

of the buccal film in grams. The following parameters were calculated from the mucoadhesive strength.(5)

$$\begin{aligned} & \text{Force of adhesion(N)} \\ &= \frac{(\text{Mucoadhesive strength(g)} \times 9.8)}{1000} \end{aligned}$$

#### In-vitro residence time

It was determined using a locally modified USP disintegration test apparatus. A 3cm long segment of porcine buccal mucosa was glued to the surface of a glass slab using acrylic glue, vertically attached to the apparatus. The mucoadhesive film was hydrated from one surface using 15 µl isotonic phosphate buffer and the hydrated surface was brought into contact with the mucosal membrane. The glass slab was vertically fixed to the apparatus and allowed to move up and down in 800 ml isotonic phosphate buffer pH 7.4 maintained at 37°, so that the film was completely immersed in the buffer solution at the lowest point and was out at the highest point. The time taken for complete erosion or detachment of the films from the mucosal surface was recorded (mean of triplicate determinations) was taken.(6)

#### Swelling index

The films were weighed and placed in a 2% agar gel plate. The 2% agar gel plate were prepared by hydrating 2g of agar powder in 98 ml hot distilled water and 25ml taken from the agar solution and poured to petri-plate which was kept in room temperature till it gets solidified. And after solidification one film from each formulation was kept over the agar gel plate. At regular time intervals, the films were removed from the plates and excess surface water was removed carefully using a filter paper. The swollen films were then reweighed and the degree of swelling was calculated using the following formula:(7)

$$\text{swelling index} = \frac{\text{wet weight} - \text{Initial weight}}{\text{Initial weight}} \times 100$$

#### In-vitro drug release

Modification of the USP Dissolution apparatus type I, was used throughout the study.

films (1cm<sup>2</sup> diameter) of each formulation was fixed to base of the central shaft of the basket (without using basket) using by a cyanoacrylate adhesive. The dissolution medium consisted of 100 ml of phosphate buffer pH 7.4 in a 100ml beaker kept inside the dissolution jar. The release study was performed at 37 ± 0.5°C with a rotation speed of 25 rpm and the release study was carried out for 9 hrs. After every hour, 5 ml sample was withdrawn from each beaker and the same volume was replaced (with the dissolution medium) to the beaker. Each withdrawn sample was filtered, diluted in 25 ml volumetric flask using pH 7.4 phosphate buffer and analysed spectrophotometrically at 219 nm. Each formulation, 2 films were tested for in-vitro release and average release was calculated.(5)

#### Numerical Optimization

The goal of optimization is to find a good set of conditions that will meet all the goals. The possible goals are maximize, minimize, target, within range, none (for responsible only) and set to an exact value (factor only). Numerical optimization will search the design space, using the models created during analysis to find factor settings that meet defined goals.

The numerical optimization finds a point that maximizes the desirability function. Desirability simply a mathematical method to find the optimum. A desirability of 1.00 means the goals were easy to reach and better results may be available.

- So, the data obtained were subjected to numerical optimization technique using design expert software version 11.

- The criteria for factors are set HPMC K4M and Carbopol 934 in the range and in that mucoadhesive strength should be maximum and in-vitro residence time should be maximum and swelling index in range and In-vitro drug release 7<sup>th</sup> hr maximum. The software recommended 5% of HPMC K4M 1% Carbopol 934 as optimum formulation which coincidence with F3 in design matrix.(8)

**Table 2: Constraints for factors and responses of Zolmitriptan mucoadhesive films for Numerical Optimization.**

Name	Goal	Lower limit	Upper limit
A: Carbopol934 (%)	Is in range	0.5	1
B: HPMC	Is in range	3	5

K4M (%)			
Mucoadhesive strength (gm)	Maximize	9.95	22.31
In-vitro residence time (min)	Maximize	78	245
Swelling index (%)	Is in range	12.79	29.7
In-vitro drug release at 7 <sup>th</sup> hr (%)	Maximize	52.606	92.088

### III. RESULT AND DISCUSSION

#### Preformulation studies

#### Identification of drug by FT-IR

The IR spectrum of pure drug was found to be similar to the standard spectrum of Zolmitriptan. FT-IR of Zolmitriptan showed three main characteristic absorption bands of at 1735

$\text{cm}^{-1}$  due to C=O stretching vibrations of amide functional group and N-H stretching band of secondary and tertiary amine appears at 3350.46  $\text{cm}^{-1}$  as a single sharp band and C-O stretching of ester group at 1259.56  $\text{cm}^{-1}$  and C-H band at 1457.27  $\text{cm}^{-1}$  as shown in figure 1.(9)




Figure 1: FT-IR spectra of Zolmitriptan

#### Melting point Determination

Melting point of Zolmitriptan was determined by capillary method. The melting point was found to be 178°C which matches with the standard melting point (178-179°C) indicating the purity of the drug sample.(3)

#### Calibration Curve of Zolmitriptan

The  $\lambda_{\text{max}}$  was found to be 219 nm. So, the standard calibration curve of Zolmitriptan was

developed at this wave length. The calibration curve was linear between 3-24  $\mu\text{g/ml}$  concentration ranges. The standard calibration curve of Zolmitriptan was determined in pH 7.4 phosphate buffer, by plotting absorbance against concentration at 219 nm. Results were tabulated in (table no 3). The  $R^2$  and slope were found to be 0.999 and 0.0928 respectively.



**Table 3: Calibration curve of Zolmitriptan in pH 7.4 phosphate buffer**

Sl.NO.	Concentration (µg/ml)	Absorbance at 219 nm (Mean ± SD)
1.	3	0.335 ± 0.0166
2.	6	0.567 ± 0.0212
3.	9	0.858 ± 0.0218
4.	12	1.124 ± 0.0209
5.	15	1.413 ± 0.0210
6.	18	1.685 ± 0.0211
7.	21	2.200 ± 0.0167
8.	24	2.136 ± 0.0212

**Evaluation of Zolmitriptan mucoadhesive films**

**Weight uniformity**

The weight of the film was found to be in the range of 23.43 to 55.31mg. Formulation F3 showing more weight as both the polymers are at maximum level.(10)

**Folding endurance**

Film did not show any cracks even after folding for more than 300 times. Hence it was taken as the end point. Folding endurance did not vary when the comparison was made between plane film and drug loaded films. It reveals that all films having satisfactory flexibility.

**Thickness of films**

The mean thickness of the mucoadhesive film was found to be in the range of 0.124 ± 0.014 mm to 0.237 ± 0.056 mm. The formulation F3,F6 and F9 showing more thickness compared to other formulation. Because the Carbopol 943 concentration is maximum on these formulations.

**Mucoadhesive strength**


Mucoadhesive strength was determined by using modified physical balance method. The procedure was followed by using porcine buccal mucosa. All the films had shown good mucoadhesive strength with the range of 9.95-22.31gm. Formulation F3 having maximum concentration of Carbopol and HPMC K4M shows maximum mucoadhesive strength. The ANOVA (Analysis of variance) for the Linear model was used to analyse the mucoadhesive strength of prepared mucoadhesive films. The statistical ANOVA evaluation showed that the model is significant as P-value was found to be 0.0013.

The **Model F-value** of 24.54 implies the model is significant. There is only a 0.13% chance that an F-value this large could occur due to noise.

The **Predicted R<sup>2</sup>** of 0.7218 is in reasonable agreement with the **Adjusted R<sup>2</sup>** of 0.8548; i.e. the difference is less than 0.2.

$$\text{Mucoadhesive strength} = +16.79 + 4.87 * \text{Carbopol 934} + 0.8300 * \text{HPMC K4M}$$

The coded equation is useful for identifying the relative impact of the factors by comparing the factor coefficients.



**Figure 2:3D surface graph of mucoadhesive strength from design expert of factors A&B**

It was conformed that increase in degree of hydration increases the adhesion but at the same time over hydration results sudden weakening in mucoadhesion and it could be owing to the disentanglement at the tissue interface. The film made using Carbopol 934 as the mucoadhesive polymer showed the highest mucoadhesive strength, and the reason for this could be optimum hydration and swelling of Carbopol 934. Carbopol 934 is a high molecular weight polymer of cross-linked acrylic acid with polyalkenyl alcohols. Carbopol 934 hydrates and swells in aqueous phase due to hydrogen bonding and electrostatic repulsion after neutralization reaction (conversion of carboxylic acids in polymer chain to carboxylates). Thus, the hydration potential of Carbopol 934 permits the film to rapidly establish contact with the mucus upon application. Hydrogen bonding and interchain penetration between Carbopol 934 and mucin components make the mucoadhesion consolidate.(10)

### In-vitro Residence time

In-vitro residence time test was carried out using modified USP disintegration test apparatus. The ANOVA (Analysis of variance) for the 2 FI model was used to analyse the in-vitro residence time of mucoadhesive films. It shown within the range of 78 to 245 minute. The P-value was found to be <0.0001 and the R<sup>2</sup> value was found to be 0.9845 respectively. The statistical ANOVA evaluation showed that the model is significant P-value of the model <0.0001. Adequate precision measures the signal to noise ratio. The ration greater than 4 is desirable. Ratio of 27.647 indicates an adequate signal. This model can be used to navigate the design space. The Model F-value of 105.62 implies the model is significant. There is only a 0.01% chance that an F-value this large could occur due to noise.

The **Predicted R<sup>2</sup>** of 0.9453 is in reasonable agreement with the **Adjusted R<sup>2</sup>** of 0.9751; i.e, the difference is less than 0.2.

$$\text{In-vitro residence time} = +149.11 + 58.83 * \text{Carbopol 934} + 16.17 * \text{HPMC K4M} + 21.75 * \text{Carbopol 934} \& \text{HPMC K4M}$$

The coded equation is useful for identifying the relative impact of the factors by comparing the factor coefficients.

It was observed In-vitro residence time increased by increased concentration of Carbopol 934 and HPMC K4M.(10)

The least in-vitro residence time were found to be with formulation F1, and the reason might be over hydration of HPMC K4M containing carboxylic groups, which form hydrogen bonds with the tissue.(11)




Figure 3: 3D surface graph of In-vitro residence time from design expert of factor A&B

### Swelling index

Swelling index was carried out by 2% agar gel plate method. The ANOVA (Analysis of variance) for the linear model was used to analyse the swelling index of the prepared mucoadhesive films. Swelling index of mucoadhesive films shown with in the range of 12.79% to 29.70%.The P-value and R<sup>2</sup> value was found to be 0.0013 and 0.8905 respectively. Adequate precision measures the signal to noise ratio. The ration greater than 4 is desirable. The ratio of 11.794 indicates an adequate signal. This model can be used to navigate the design space.

The **model F-value** of 24.39 implies the model significant. There is only a 0.13% chance that an F-value this large could occur due to noise. P-values less than 0.0500 indicate model terms are significant in this case B is significant model term. Values greater than 0.01000 indicates the model

terms (not counting those required to support hierarchy), model reduction may improve your model.

The **predicted R<sup>2</sup>** of 0.7790 is in reasonable agreement with the **Adjusted R<sup>2</sup>** of 0.8540; i.e, the difference is less than 0.2.

$$\text{Swelling index} = +21.52 + 6.12 * \text{Carbopol 934} + 1.37 * \text{HPMC K4M}$$

The equation in term of coded factors can be used to make prediction about the response for given levels of each factor. The coded equation is useful for identifying the relative impact of the factors by comparing the factor coefficients.

It was assumed that the high hydrophilicity nature of polymer in F9 resulted in extreme swelling as compared to other formulations. There exists a direct relationship between the swelling index and presence of

polymer Carbopol. It is formed by ‘polyacrylic acid chains’ cross linking. It is well known statement that swelling reduces generally due to cross-linking of polymeric chains. But the presence of carboxylic acid (COOH) group in the polymeric chains of Carbopol gets converted to carboxylate groups (COO-) after neutralization that leads to self-

repulsion of polymeric chains themselves and forms hydrogen bonds with water. This particular characteristics of Carbopol marks this polymer as one of the swellable polymers despite being cross-linked. The quicker the polymer swells, the quicker the bonds between mucus and the polymer form, hence the adhesion to mucus occurs quicker.(10)




Figure 4: 3D surface graph of swelling index from design expert of factor A&B

**In-vitro drug release at 7<sup>th</sup> hr**

In-vitro drug release of mucoadhesive film was performed in phosphate buffer (pH 7.4) using Modification USP dissolution apparatus type-I. Since the dose of the drug in each film 2.5 mg. Volume of the dissolution is reduced to 100 ml and to facilitate the complete immersion of the film in the dissolution media. Separate beaker with dissolution media is placed in the dissolution basket. The samples were withdrawn at different time intervals up to 9 hrs and was analysed using UV-spectrophotometer at 219nm.

ANOVA (Analysis of variance) for the linear model was used to analyse the % in-vitro drug release at 7<sup>th</sup> hr of the prepared mucoadhesive films. The statistical ANOVA evaluation showed that the model is significant and the P-value of the model was found to be 0.0169.

The **Model F- value** of 8.69 implies the model is significant. There is only a 1.69% chance that an F-value this large could occur due to noise.

$$\text{Invitro drug release at 7}^{\text{th}} \text{ hr} = +69.70 +16.61 *A +5.78 *B$$

The equation in terms of coded factors can be used to make prediction about the response for given levels of each factor. The coded equation is useful for identifying the relative impact of the factors by comparing the factor coefficients.

According to the actual factors equation, concentration of both Carbopol 934 and HPMC K4M are having positive effect on % drug release. Formulation F3 showed maximum drug release in 7<sup>th</sup> hr (i.e.92.088%). Because the concentration of polymers was maximum in formulation F3. Polymer concentration is a major factor effecting the drug release of mucoadhesive films.(10) Increases the concentration of Carbopol 934 and HPMC K4M showed extended drug release.(11)






Figure 5: 3D plot of In-vitro drug release at 7<sup>th</sup> hr from design expert of factors A&B

Optimized formulation of mucoadhesive film from design expert

Table 10: Optimized formulation from design expert

No.	Carbopol (%)	HPMC K4M (%)	Mucoadhesive strength (gm)	In-vitro Residence time (min)	Swelling Index (%)	In-vitro drug release at 7 <sup>th</sup> hr (%)	Desirability
DOE PREDICTION	1	5	22.495	245.861	29.001	92.088	0.893
ACTUAL RESULT(F3)	1	5	22.31	245	29.7	92.088	

Formulation F3 found to be as optimized formulation.

The optimized formulation suggested the composition as follows:

Carbopol (A)= 1%, HPMC K4M (B)= 5%, Mucoadhesive strength= 22.495 gm, In-vitro residence time= 245.861 min, Swelling index= 29.001 %, In-vitro drug release 7<sup>th</sup> hr= 92.008% with a desirability 0.893.

IV. CONCLUSION

Aim of the study was to formulate and evaluate the mucoadhesive film of an anti-migraine drug Zolmitriptan for mucoadhesive drug delivery. From this study the following conclusions were drawn:

- Pre-formulation studies were carried out for the purpose of identifying the drug by FT-IR, calibration curve was constructed to estimate the drug using UV- visible spectroscopy, melting point determination by using capillary method.

- FT-IR spectra of drug with other excipients indicated that there is no interaction between the drug and the excipients.
- The mucoadhesive films were formulated using Carbopol 934 and HPMC K4M by solvent casting method. The face centered composite design has planned to evaluate the influence of excipients on various parameters.
- The formulated mucoadhesive films were evaluated for different characterization tests such as swelling index, in-vitro drug release, mucoadhesive strength, in-vitro residence time and all the formulations showcased satisfactory results.
- The excipients concentrations exhibited great effect on the evaluation parameters Mucoadhesive strength, In-vitro residence time, in-vitro drug release and swelling index.
- The results obtained from design expert version 11 in the form of 3D plots indicated that an increase in the concentration of Carbopol 934 increased mucoadhesive strength, in-vitro residence time, in-vitro drug

release and swelling index. Comparatively Carbopol 934 has shown greater influence than HPMC K4M as shown by their coefficient of the factors.

- The optimized formulation suggested by numerical optimization method as follows

Carbopol 934 = 1%, HPMC K4M = 5%, Mucoadhesive strength = 22.295 gm, In-vitro residence time = 245.861 min, Swelling index = 29.001%, In-vitro drug release at 7<sup>th</sup> hr = 92.088%, Desirability = 0.893.

With these concentrations, the suggested responses were 22.31 gm for mucoadhesive strength, 245 min for in-vitro residence time, 29.7% for swelling index, 92.088% for in-vitro drug release at 7<sup>th</sup> hr. The practical results of the optimized formulations were closely related to the predicted results.

- The mechanism of drug release of the optimized formulation F3 was found to be non-fickian transport with Zero order release.

- Future plan of action

Optimized formulation can be further evaluated for in-vivo studies.

**Acknowledgement:** I would like to acknowledge and thank my guide Dr. Rama Bukka for her encouragement and guidance throughout the course of my research work and I want to give a special thanks to the Vision Group of Science and Technology, Bangalore, Karnataka for the GRD-178 grant that allowed for the purchase and use of nanoparticle analyzer SZ 100 made by Horiba Scientific, Kyoto, Japan.

#### REFERENCE

- [1]. Messoud A. Migraine. The New England Journal of Medicine. 2020;383: 1866-1876.
- [2]. Boddupalli BM, Mohammed ZNK, Nath A. R, Banji D. Mucoadhesive drug delivery system: An overview. J Adv Pharm Technol Res. 2010;1(4):381-7.
- [3]. Ayalasomayajula LU, Earle RR, Vyasa Murthy A. Formulation and evaluation of rapidly dissolving films of zolmitriptan. Der Pharm Lett. 2016;8(10):173-80.
- [4]. Ansari M, Sadarani B, Majumdar A. Optimization and evaluation of mucoadhesive buccal films loaded with resveratrol. J Drug Deliv Sci Technol [Internet]. 2018;44:278-88. Available from: <https://doi.org/10.1016/j.jddst.2017.12.007>
- [5]. J. Ravi Kumar Reddy YIMKP. C. Formulation and evaluation of mucoadhesive buccal films of amiloride hydrochloride. J Glob Trends Pharm Sci. 2012;3(3):828-35.
- [6]. Mane PP, Bushetti SS, Keshavshetti GG. Development and in vitro evaluation of mucoadhesive buccal films of nebiivolol. Indian J Pharm Sci. 2014;76(2):166-9.
- [7]. Mukherjee D, Bharath S. Design and Characterization of Double Layered Mucoadhesive System Containing Bisphosphonate Derivative. ISRN Pharm. 2013;2013:1-10.
- [8]. Dhoot N, Vidyasagar G. Formulation and Optimization of Mucoadhesive Films of Some Anti-fungal Drugs by PVA and Gelatin Based Technique. 2015;(April):184-94.
- [9]. Eglal M, Hammid SNA Al. Design Zolmitriptan Liquisolid Orodispersible Tablets and Their in Vitro Evaluation. Int J Pharm Pharm Sci. 2016;9(1):297.
- [10]. KGB. Formulation and Evaluation of Mucoadhesive Herbal Buccal Patch of Psidium Guava L. J Curr Pharma Res. 2014;5(1):1372-7.
- [11]. Anupam P, Ashwani M, Praveen M. Formulation and evaluation of gastroretentive mucoadhesive films of Captopril. Pharmacia. 2013;2(June):31-8.